Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

100%

9 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

9(100.0%)

9Total

Phase 4(9)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT00294567Phase 4Completed

Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)

Role: collaborator

NCT00212004Phase 4Terminated

Pioglitazone Protects Diabetes Mellitus (DM) Patients Against Re-Infarction (PPAR Study)

Role: collaborator

NCT00265239Phase 4Completed

Pilot Study of Edaravone to Treat Acute Myocardial Infarction

Role: collaborator

NCT00139386Phase 4Completed

Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial

Role: collaborator

NCT00454662Phase 4Completed

Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)

Role: collaborator

NCT00134160Phase 4Completed

OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study

Role: collaborator

NCT00144144Phase 4Unknown

A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes

Role: collaborator

NCT00285519Phase 4Completed

Japan Morning Surge-1 Study

Role: lead

NCT00225849Phase 4Unknown

Japanese Primary Prevention Project With Aspirin

Role: collaborator

All 9 trials loaded